Our Finance Guide
  • Home
  • Loans
  • Tax
  • Credit Cards
  • Investing
No Result
View All Result
  • Home
  • Loans
  • Tax
  • Credit Cards
  • Investing
No Result
View All Result
Our Finance Guide
No Result
View All Result
Home Investing

Cramer’s Investing Club: Recent drop in a portfolio drug stock only a minor setback

admin by admin
December 24, 2021
in Investing
0
Real Estate Investing & More

After the big run last week, Eli Lilly (LLY) shares have backed off to a bit to the mid-$260s due to a combination of investors booking profits where they had them in a volatile market and rotational pressure from the risk-on attitude of Tuesday’s rally.

What sent shares of Eli Lilly to new highs last week, including a roughly 10% gain on a single day, was an Investor Day event that was nothing short of impressive. They raised 2021 revenue and earnings per share guidance above consensus thanks to additional revenue from Covid antibodies sales. And their 2022 outlook was much better than what anyone expected.

Related articles

U.S. ready to help Mexico finance solar plans, Lopez Obrador says

These Are the Best Ways to Finance a Car Purchase in 2023

See, heading into the event, many analysts feared 2022 would be a down earnings year for Lilly due in part to a reduction in Covid antibody revenue and a step up in investment to fund their large phase 3 programs and support their massive new product launches. But Eli Lilly put an end to that narrative last week.

  • Their sales outlook was higher than estimates at the top end of the range.
  • The adjusted earnings per share guide of $8.50 to $8.65 crushed expectations of $8.13 thanks to operating margin expansion.
  • If Eli Lilly delivers the 32% operating margin in guidance, that would mean the company has expanded margins by over 1,100 basis points since 2016.
  • And by the way, if the FDA ever approves the use of Eli Lilly’s second generation Covid antibody cocktail treatment, those sales will represent pure upside to the numbers.

On top of guidance, Eli Lilly showcased a pipeline that we think is the most valuable in the industry. The two most important medicines in the pipeline with commercial opportunities greater than $10 billion are tirzepatide for the treatment of type 2 diabetes and obesity (an area of increased focus for Lilly) and donanemab for Alzheimer’s. Both are expected to be approved by the FDA in 2022 and support Eli Lilly’s top-tier growth for years. In addition to the great work Eli Lilly is doing in obesity and neuroscience, management highlighted the opportunities that exist in their oncology and immunology pipelines.

The Investor Day event was everything we had hoped for and confirmed our belief that Eli Lilly has the strongest and cleanest multi-year top and bottom-line growth story in all of large-cap pharma. The top-line growth is fueled by recent and upcoming launches, with Lilly on track to deliver 20 new medicines in a 10-year period beginning in 2014. And the earnings growth is coming from management’s superior productivity and ability to expand margins up to the mid-to-high 30s in the medium term.

 

Read more…

admin

admin

Related Posts

U.S. ready to help Mexico finance solar plans, Lopez Obrador says

MEXICO CITY, Dec 20 (Reuters) - The United States is offering to help Mexico with loans to finance planned solar power stations in the northern state...

These Are the Best Ways to Finance a Car Purchase in 2023

Car financing is an important part of buying a vehicle and can be the difference between getting your ideal car and settling for something less. A...

SEVEN financial predictions for the year ahead

1. High inflation is not going awayWe are heading into major macroeconomic headwinds and these winds won’t die down for the foreseeable future. Inflation is being...

As funds run dry, Idaho Housing and Finance will soon pause emergency rental assistance program

The Idaho Housing and Finance Association plans to pause applications for emergency rental assistance funds on Dec. 29 because federal funds are quickly running dry for...

4 Tips for investing during the crypto market instability

The crypto market is infamously known for its extreme instability. As a matter of fact. the term volatile” has almost become synonymous with the crypto industry...

Next Post
4 personal loan lenders to consider if you need to borrow as little as $1,000

Student Loan Forgiveness: Eligibility and how to apply

Today’s the last day to opt out of the December child tax credit check. What to know

PERSONAL FINANCE Some Americans may receive more stimulus money this tax season

Credit card showdown: Chase Ink Business Preferred vs. Ink Business Premier

Credit card showdown: Chase Ink Business Preferred vs. Ink Business Premier

No Result
View All Result

Subscribe Us

By clicking subscribe, I authorize: (1) Our Finance Guide to use and share my information in accordance with its Terms of Service and Privacy Policy, and (2) Our Finance Guide or third-party companies, including Our Finance Guide’s business partners, to contact me by email with offers for goods and services at the email address provided. Please note that the information you have provided to us may be supplemented with additional information obtained from other sources.

RECOMMENDED

Best credit cards for bad credit: Top online credit card lenders of 2022
Credit Cards

Best credit cards for bad credit: Top online credit card lenders of 2022

See the Average Child Tax Credit in Your State
Tax

See the Average Child Tax Credit in Your State

CATEGORIES

  • Credit Cards
  • Investing
  • Loans
  • Tax
  • Uncategorized

Subscribe Us

By clicking subscribe, I authorize: (1) Our Finance Guide to use and share my information in accordance with its Terms of Service and Privacy Policy, and (2) Our Finance Guide or third-party companies, including Our Finance Guide’s business partners, to contact me by email with offers for goods and services at the email address provided. Please note that the information you have provided to us may be supplemented with additional information obtained from other sources.

© 2022 Our Finance Guide, All Rights Reserved.

  • Contact Us
  • Privacy Policy
  • Terms Of Service
  • Unsubscribe
No Result
View All Result
  • Home
  • Loans
  • Tax
  • Credit Cards
  • Investing

© 2022 Our Finance Guide, All Rights Reserved.